News Article
CapVest Partners acquiring €10bn pharma group STADA Arzneimittel
European investment firm CapVest Partners has secured a definitive agreement to acquire a majority (70%) stake in STADA Arzneimittel AG from private equity firms Bain Capital and Cinven, valuing the German pharmaceutical giant at approximately €10bn including debt.
The transaction positions CapVest as the new controlling shareholder while Bain Capital and Cinven retain minority stakes after eight years of ownership, reflecting their continued confidence in STADA’s growth trajectory.
The €10bn valuation represents a near-doubling of STADA’s enterprise value since Bain/Cinven’s 2017 acquisition for €5.3 billion
Under Bain/Cinven, STADA achieved €4.06bn in 2024 revenue, a 9% compound annual sales growth rate, and more than doubled EBITDA since 2017.
Closing is expected in early 2026, subject to regulatory approvals.
